PubRank

A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib (TRAVERSE)

Clinical Trial ID NCT01387555

PubWeight™ 18.07‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01387555

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 2013 4.86
2 New viruses for cancer therapy: meeting clinical needs. Nat Rev Microbiol 2013 1.72
3 Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology 2013 1.36
4 Trial Watch:: Oncolytic viruses for cancer therapy. Oncoimmunology 2014 1.22
5 Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2015 1.06
6 Oncolytic Poxviruses. Annu Rev Virol 2014 0.96
7 Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses. Mol Ther Methods Clin Dev 2016 0.86
8 Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade. Viruses 2016 0.85
9 Trial Watch-Oncolytic viruses and cancer therapy. Oncoimmunology 2015 0.83
10 Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1. Front Oncol 2014 0.82
11 Isolation of vaccinia JX594 from pustules following therapy for hepatocellular carcinoma. BMC Cancer 2015 0.79
12 Oncolytic Viruses: Therapeutics With an Identity Crisis. EBioMedicine 2016 0.79
13 Development of systemic therapy for hepatocellular carcinoma at 2013: updates and insights. World J Gastroenterol 2014 0.78
14 Assessment of current virotherapeutic application schemes: "hit hard and early" versus "killing softly"? Mol Ther Oncolytics 2015 0.77
15 New frontier in liver cancer treatment: oncolytic viral therapy. Hepatology 2013 0.75
Next 100